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ABSTRACT
Purpose: A number of studies have indicated that the
tumor proliferation marker MIB-1 and cell cycle inhibitor
p27Kip1 expression are of prognostic importance in a variety
of cancers. The present study was performed to evaluate the
prognostic value of these molecules in Wilms’ tumors.
Experimental Design: MIB-1 and p27Kip1 expressions
were investigated by the means of immunohistochemical
analysis of 62 Wilms’ tumor. Patients were preoperatively
treated by chemotherapeutic agents and had a mean fol-
low-up of 5.7 years.
Results: MIB-1 and p27Kip1 were expressed in normal
kidney tissues and in the three main components of Wilms’
tumor, i.e., the blastemal, epithelial, and stromal cells. In
Wilms’ tumors, the percentage of MIB-1-positive cells in the
blastema ranged between 0 and 42% (mean, 9.4%) and in
the epithelial component between 0 and 53% (mean, 19.9%),
with a significant difference (P < 0.01). The percentage of
blastemal p27Kip1-positive cells ranged between 3 and 85%
(mean, 55.1%) and for the epithelial component between 1
and 87% (mean, 59%). There was a significant inverse
relationship between blastemal MIB-1 and p27Kip1 expres-
sion in Wilms’ tumor. Univariate analysis showed that blast-
emal MIB-1 and p27Kip1 expression were indicative for clin-
ical progression and tumor-specific survival. In a
multivariate analysis, blastemal MIB-1 and p27Kip1 protein
expression proved to be an independent prognostic for clin-
ical progression besides stage.
Conclusions: It was concluded that both MIB-1-based
proliferative activity and p27Kip1 protein expression in the
blastema have prognostic impact in Wilms’ tumor.
INTRODUCTION
Wilms’ tumor is a pediatric malignancy of the kidney and
one of the most common solid tumors in children (1). Currently,
the prediction of outcome is based mainly on the histopathology
and stage of disease at the time of resection (2). Identification of
factors predictive of the aggressive growth of this malignant
tumor would enable stratification of patients for optimal strat-
egy. Predicting the clinical behavior of Wilms’ tumor can
be difficult; one approach is to identify molecular prognostic
markers (3).
Advances in cell cycle research have led to the identifica-
tion of protein markers responsible for the regulation of cell
proliferation. The Ki-67 monoclonal antibody has been devel-
oped and used in evaluating cellular proliferation rates of ma-
lignant tumor (4–7). More recently, the monoclonal antibody,
MIB-1, has been developed using recombinant portions of the
Ki-67 nuclear antigen as immunogen. MIB-1 recognizes the
Ki-67 nuclear antigen, which is associated with cell proliferation
and is found throughout the cell cycle (G1, S, G2, and M phases)
but not in resting (G0) cells (8). The clinical value of prolifer-
ation markers for prognostication of nephroblastoma is still
subject of debate (9–11).
The p27Kip1 protein is a cyclin-dependent kinase inhibitor,
affecting the G1-S traverse in response to extracellular signals
(12–14). In experimental models, the p27Kip1 protein is conspic-
uously present in quiescent cells and in cells undergoing termi-
nal differentiation, whereas this marker is absent during cell
division (15). There is increasing evidence that low expression
of p27Kip1 is an important clinical marker for disease progres-
sion in many tumor types (16–23).
In the present study, we investigated the expression and the
prognostic value of the Ki-67 (MIB-1) proliferative index (PI)
and p27Kip1 expression in nephroblastoma using immunohisto-
chemistry on paraffin-embedded material.
MATERIALS AND METHODS
Patients. During the period 1987–1999, 62 patients with
nephroblastoma were treated by neoadjuvant chemotherapy and
subsequent tumor nephrectomy. Twenty-six patients (42%)
were female, and 36 patients (58%) were male. Patients were
treated according to Societe´ International d’Oncologie Pedi-
atrique (SIOP) protocol 9 and some according to 93-01, receiv-
ing actinomycin D and vincristine. After treatment, patients
were followed regularly, and all data concerning diagnosis,
treatment and follow-up were stored in a database. The mean
overall follow-up period was 5.7 years, and the mean age at
operation was 4.7 years. Clinical progression was defined as
histologically or cytologically proven local recurrence or the
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appearance of distant metastases. Tumor death was defined as
death due to direct effect of metastases.
Sample Selection. All nephrectomy specimens were
fixed in 10% buffered formalin and embedded in paraffin. The
tumor stage was done according to the SIOP trial protocol
established in the SIOP meeting in Stockholm in 1994 (24).
Among the tissue blocks of tumors from individual patients
having the classical type of tumor, i.e., tumor samples contain-
ing the three different cell types (blastema, epithelial, and stro-
mal), different samples were selected throughout the tumor. In
addition, adjacent normal kidney tissue (n 26) was taken from
each patient. Samples containing any aspect of nephroblastosis
were excluded from this series.
Antibodies. These primary antibodies were used as fol-
lows: mouse monoclonal antibodies against Ki-67 (MIB-1; Im-
munotech, Marseille, France) and against p27Kip1 (clone 1B4;
Novocastra Laboratories Ltd., Newcastle, United Kingdom).
The specificity and characteristics of these antibodies have been
published elsewhere (8, 13, 14).
Immunohistochemistry. The peroxidase-antiperoxidase
immunohistochemistry technique was used and applied to serial
sections (5 m) from all samples, which were mounted on
3-aminopropyl-trietoxysilane (Sigma Chemical Co., St. Louis,
MO) coated glass slides and subsequently incubated overnight
at 60°C incubator. To enhance antigen exposure, slides were
microwaved at 700 W in 0.1 M citrate buffer at pH 6.0 for 15
min. Sections were incubated with 10% normal rabbit serum
(Dako) in PBS (PBS) 5% BSA (BSA) for 15 min and subse-
quently incubated with the primary antibody MIB-1 for 30 min
at room temperature and overnight with p27Kip1 at 4°C. The
antibodies were diluted in PBS/5%BSA at 1:20 for MIB-1 and
p27Kip1. After being incubated with rabbit-antimouse antibody,
the peroxidase-antiperoxidase complex (Dako) was diluted in
PBS/5%BSA and incubated for 30 min, after which antigen-
antibody binding was visualized with diaminobenzidine tetra-
hydrochloride dihydrate (Fluka, Neu-Ulm, Germany). Replac-
ing the primary antibody by PBS/5%BSA included negative
controls.
Immunostaining Analysis (Quantification). The slides
were evaluated by two independent observers, using a standard
light microscope with a 40 objective and equipped with an
ocular grid. Cells were considered positive regardless of the
intensity or location of nuclear staining. Stromal cell staining
was excluded from the counting process. Also, the tumor-
infiltrating lymphocytes cells were avoided in the MIB-1 eval-
uation. The subjective assessment of the distribution of posi-
tively labeled cells was identical in all cases. MIB-1 and p27Kip1
expression (i.e., the percentage of MIB-1 and p27Kip1-positive
tumor cells) was derived by counting at least 1000 tumor cells
in five randomly selected fields of view. Fields containing areas
of extensive necrosis were excluded from evaluation. For MIB-1
PI, two categories were defined according to the percentage of
stained nuclei PI  5% and PI  5%. The cutoff value of 5%
was statistically known to be the lowest value at which discrim-
ination with a significant probability value was achieved. On the
basis of the previous studies, for p27Kip1 protein, a cutoff value
of 50% of the tumor cell was used (19, 20).
Statistical Analysis. Statistical analysis was performed
using the SPSS 9 software package. The association between
MIB-1 and p27Kip1 expression and clinicopathological features
was analyzed using 2 test. MIB-1 and p27Kip1 expression in
normal kidney was studied using the Spearman rank correlation
test because the data were not normally distributed. For analysis
of survival data, Kaplan-Meier curves were constructed, and the
log-rank test was performed. Multivariate analysis was per-
formed using Cox’s proportional hazards model with P  0.05
considered statistically significant.
RESULTS
Clinicopathological Findings. The pT-stage distribution
was T1 in 22, T2 in 19, and T3 in 21 patients. Clinical progres-
sion occurred in 14 patients (23%) and 7 patients (11%) died
from their tumor. At the end of the follow-up period, 55 patients
were alive.
MIB-1 Expression in Normal Kidney and Wilms’ Tu-
mor Tissues. The PI of normal renal tissue, i.e., the percent-
age of MIB-1-positive cells ranged between 0 and 3% (1.5  1;
mean  SD; Table 1 and Fig. 1A). In Wilms’ tumor, immuno-
staining was localized in the blastemal and epithelial nuclei. The
frequency of positive nuclei varied from specimen to specimen
and among tumors having the same stage. In 19% of cases, the
highest PI was observed in the peripheral zone of malignant
tissues close to the supportive stroma. The mean percentage of
blastemal MIB-1-positive cells was 9.4  10 (range, 0–42%),
whereas for epithelial cells, MIB-1 PI was 19.9 18.6% (range,
0–53%; Table 1). In the lesions studied, the PI for the epithe-
lium was significantly higher than those found for the blastema
(Spearman rank correlation coefficient, P  0.01). In 7 of 62
(11%) specimens, derived from tumors of various stages, no
labeling with MIB-1 antibody was found. At a cutoff PI of 5%,
MIB-1-positive blastemal and epithelial cells were found in 38
(61%) and 41 (66%), respectively, of the Wilms’ tumors stud-
ied. A correlation between MIB-1 and pathological stage was
not found for blastema or epithelium (Table 2).
p27Kip-1 Expression in Wilms’ Tumor Tissues. The
percentage of p27Kip1-positive cells in normal renal tissue
Table 1 Distribution of MIB-1 and P27Kip1 expression in Wilms’ tumor tissues and normal renal tissues
Wilms’ tumors tissues
MIB-1 P27Kip1 Normal renal tissues
Blastema Epithelial Blastema Epithelial MIB-1 P27Kip1
Mean  SD 9.4  10% 19.9 18.6% 55.1  24% 59 27% 1.5  1% 21  14.2%
Range 0–42% 0–53% 3–85% 1–87% 0–3% 0–55%
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ranged between 0 and 55% (21  14.2; Table 1 and Fig. 1B). In
Wilms’ tumors, p27Kip1 was expressed at variable levels in the
blastemal and epithelial nuclei, usually with a low background
and with a rather diffuse staining pattern (Fig. 1D). The number
of cells expressing p27Kip1 as well as staining intensity varied
from case to case. Infiltrating mature lymphocytes showing
positive p27Kip1 staining served as an internal positive control.
The mean percentage of blastemal p27Kip1-positive cells was
55.1  24% (range, 3–85%), and for the epithelium p27Kip1, it
was 59  27% (range, 1–87%; Table 1). The p27Kip1 scores of
blastema and epithelial tumor cells showed a significant inverse
correlation compared with those found in normal tubular epi-
thelial cells, i.e., correlation coefficient of r0.42, P 0.05,
r  0.58, P  0.01), respectively. Using the cutoff value of
50%, p27Kip1 positivity for blastemal and epithelial cells was
found in 35 (57%) and 45 (73%), respectively, of the Wilms’
tumors studied. A correlation between p27Kip1 and pathological
stage was not found in either blastema or epithelium (Table 2).
Relationship between MIB-1 PI and p27Kip1 PI. In
most specimens, the proportion of p27Kip1-positive tumor cells
was greater than the proportion of MIB-1-positive tumor cells.
An inverse correlation between blastemal p27Kip1 expression
and MIB-1-based proliferative activity was found, with a cor-
relation coefficient of0.311 (P 0.01; Fig. 2). Notably, in the
scatterplot shown in Fig. 2, a separate population of Wilms’
tumor becomes apparent (indicated by arrows).
Table 2 Relationship between pT stage and blastemal and epithelial expression of MIB-1 and p27Kip1a
Stage
MIB-1 p27Kip1
Blastemal Epithelial Blastemal Epithelial
T1 16 (73) 15 (68) 10 (46) 14 (64)
T2 11 (58) 14 (74) 12 (63) 13 (68)
T3 11 (52) 12 (57) 13 (62) 18 (86)
Total 38 (61) 41 (66) 35 (57) 45 (73)
P 0.05 0.05
a Data are presented as numbers of MIB-1-positive (cutoff value 5%) and p27Kip1-positive (cutoff value 50%) Wilms’ tumors, percentages
between brackets.
Fig. 1 Comparison of MIB-1 antigen and p27Kip1 in nonneoplastic and nephroblastoma tissues. Normal renal tissue sections and nephroblastoma
tissues were immunostained for MIB-1 (A, C) and P27Kip1 (B, D), respectively. Slides were counterstained with hematoxylin (magnification, 400).
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Prognostic Value of MIB-1 and p27Kip1. Univariate
analysis, using the log-rank test, showed prognostic significance
of blastemal MIB-1 PI and p27Kip1 expression for clinical
progression and tumor-related death (Table 3, Figs. 3 and 4). In
contrast, the epithelial MIB-1 PI and p27Kip1 expression did not
show any prognostic value (Table 3). To assess whether MIB-1
and p27Kip1 expression had any prognostic impact, a multiva-
riate Cox’s regression analysis was done, including the param-
eters pT stage, MIB-1, and p27Kip1 expression. The parameters
that were not dichotomic were dichotomized as follows: pT
stage was divided as pT1–2 versus pT3; for MIB-1 was classi-
fied as PI  5% versus PI  5%; and for p27Kip1 as PI  50%
versus PI  50%. Accordingly, both MIB-1 and p27Kip1 blast-
emal expression could be identified as independent prognostic
variable for clinical progression besides stage (Table 4).
DISCUSSION
The assessment of the presence of cell cycle-related pro-
teins may yield important information about the biological be-
havior of a tumor. A variety of methods have been used for
estimation of the PI of human cancer. One of these methods is
scoring of mitotic figures. However, mitosis represents only a
short phase in the active cell cycle, and accordingly, only 1–5%
of all DNA-synthesizing cells is microscopically detectable
(24). In recent years, MIB-1 (a true equivalent of Ki-67) has
been proven to be the best proliferation marker for routine use
in formalin-fixed and paraffin-embedded tissue sections (4, 7,
24). The present study was carried to investigate whether the
proliferative activity represented by MIB-1 and the immunore-
activity of p27Kip1 has prognostic value in nephroblastoma. All
patients in this study received chemotherapy before operation.
The prognostic value of the Ki-67 proliferative tumor
marker as assessed by the MIB-1 antibody is well established in
several types of tumors, e.g., squamous cell carcinoma of the
esophagus, non-Hodgkin’s lymphoma, non-small cell lung can-
cer, cervical cancer, pancreatic head cancer, prostatic cancer (7,
25–29), as well as by Delahunt in Wilms’ tumor (11). In the
present study, a prognostic value of proliferative activity of the
blastemal, i.e., blastemal MIB-1 expression was found for clin-
ical progression and tumor-specific survival. The epithelial
component of individual tumors showed significantly higher
MIB-1 scores than those found for the blastema, an observation
that was also described by Khine et al. (10). The lack of
correlation between PI as measured with MIB-1 antibody and
tumor stage may be explained by the decrease in nuclear Ki-67
immunostaining as a result of hypoxia at increasing distances
from the surrounding capillaries in tumors of larger size (30).
Lack of MIB-1 staining has been observed in 11% of all
tumors studied. This very low proliferative activity in nephro-
blastoma tissue has also been reported by other investigators
(10). Also, the observation that tumor stroma shows less prolif-
erative activity than blastemal and epithelial components (10,
31) suggested that the stroma of Wilms’ tumor is of dual
character consisting of both desmoplastic and tumor elements.
This proliferative activity is derived mainly from both neoplas-
tic and nonplastic tissues. However, the precise histogenetic
relation between the blastema and the stroma is as yet not
conclusively established and needs further study. In general, this
observation is in line with the notion that Wilms’ tumor is
composed of different tissues with a strong variation in prolif-
eration and differentiation potentials and patterns of marker
expression.
Alteration in the p27Kip1 expression has been described in
a number of human tumors (32). In this study, we show that high
levels of the cell cycle-dependent kinase inhibitor p27Kip1 are
associated with poor survival in nephroblastoma. This is con-
tradictory to most tumors, where a low p27Kip1 is associated
with poor prognosis, e.g., colorectal, epithelial, ovarian, breast,
gastric, Barrett’s, esophageal, non-small cell lung, and prostatic
Table 3 Univariate analysis of prognostic markers
Variable
Blastemal Epithelial
Clinical progression
Tumor-specific
survival Clinical progression
Tumor-specific
survival
2 Pa 2 Pa 2 Pa 2 Pa
MIB-1 5.08 0.02 4.02 0.05 2.9 0.09 0.15 0.71
p27Kip1 8.24 0.004 4.12 0.04 0.05 0.82 0.15 0.70
a Log-rank test.
Fig. 2 Relationship between blastemal MIB-1 proliferative index (PI)
and p27Kip1 expression in nephroblastoma. Scatterplot of MIB-1 PI
versus p27Kip1 PI with regression line showing a correlation of the two
cell cycle regulators using Spearman’s correlation coefficient. Arrows
indicate a separate population of Wilms’ tumor.
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carcinomas (18–21, 32–37). The findings are, however, consist-
ent with previous evidence that p27Kip1 is often expressed at
relatively high levels in human cancer cell lines, which are
additionally characterized by increased the expression of cyclin
D1 or cyclin E (38, 39). Also, high levels of p27Kip1 are associated
with poor survival in invasive cervical carcinoma (16)
High proliferative activity, as defined by expression of the
Ki-67 analysis (MIB-1) antibody, has been shown to correlate
with reduced p27Kip1 in lymphoid neoplasms, carcinoma of the
oral cavity, and endocrine tumors, including pituitary, thyroid,
and parathyroid gland hyperplasia (14, 40–43). In contrast,
studies on colorectal and breast cancer showing no correlation
between tumor cell proliferation and p27Kip1 have been reported
(18, 21). The present study demonstrates that increased p27Kip1
expression correlates to some extent with decreased prolifera-
tive activity measured by MIB-1 (Fig. 2).
This study may indicate that MIB-1 and p27Kip1 protein
contribute to or reflect cell proliferation by alteration of the
kinetic behavior in primary treated Wilms’ tumor. Because in
individual cases MIB-1 and p27Kip1 do not have an inverse
correlation, other factors than p27Kip1 may also be involved in
proliferative activity of Wilms’ tumor. The small separate pop-
ulation of Wilms’ tumors of mainly low p27Kip1 activity and
low MIB-1 PI (Fig. 2) may thus indicate that in these tumors
p27Kip1 does not play an important role in regulation of prolif-
eration.
A limitation of this study could be that it has been per-
formed on Wilms’ tumors after pretreatment with chemother-
apy. Chemotherapy is known to affect the cellular compartments
of the Wilms’ tumor, the blastemal component in particular. In
the mean time, we have been able to perform a similar immu-
nohistochemical study on material derived from patients that did
not receive any therapy before surgery. Preliminary data of
staining of a pilot group of these tumors demonstrated that
overall scores of the blastemal as well as epithelial cells in these
tissues significantly differ from the scores of the pretreatment
Fig. 3 Kaplan Meier curves showing a relationship between blastemal
MIB-1 expression and clinical progression (A) and survival (B), respec-
tively. Censored patients are indicated by a tic marks along their line.
Number of patients/group is shown between brackets.
Fig. 4 Kaplan-Meier curves showing a relationship between blastemal
p27Kip1 expression and clinical progression (A) and survival (B), respec-
tively. Censored patients are indicated by a tic marks along their line.
Number of patients/group is shown between brackets.
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group described in the present article. Because most of the
patients responded well upon chemotherapeutic treatment, it
was not to our surprise to observe that proliferation was af-
fected, and MIB-1 scores were lower in the pretreatment group,
whereas the contrary applied to the p27Kip1 marker.
Having access to material derived from a considerable
number of patients with a good stage distribution and clinical
data, the aim of the present study was to determine those factors
that could predict the clinical outcome of patients after chemo-
therapy and surgery. In that way, the remaining proliferative
activity in tumor tissue after chemotherapeutic treatment may be
of prognostic value for predicting the course of disease after
surgical removal of the tumor.
In conclusion, here, we report that there is an increase in
the p27Kip1 protein levels in nephroblastoma tissues after chem-
otherapy compared with normal renal tissues. The blastemal
expression of p27Kip1 showed a consistent and strong associa-
tion with poor prognosis. The results support the conclusion that
MIB-1 and p27Kip1 are relevant markers for assessing the pro-
liferative activity and tumor cell dynamic of Wilms’ tumor.
Therefore, these biological predictors may potentially provide
the clinical oncologist with a biological rational in identifying
patients at high risk of tumor recurrence and to guide the
adjuvant chemotherapy and/or radiotherapy.
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